Seegene Inc.

Seegene Inc. is a biotechnology company headquartered in South Korea, founded in 2000. The company's mission is to improve global quality of life by making molecular diagnostics more accessible. With over 250 molecular diagnostics reagent kits and a range of instruments and consumables, Seegene has established itself as a leader in the industry. The company has witnessed significant growth, with a revenue exceeding $1 billion and 65% gross margins, a majority of which comes from outside Korea. Notably, Seegene played a crucial role in the fight against COVID-19 by providing testing kits during the pandemic.

Following its success, Seegene is undergoing a transformation, shifting from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics. The company is focused on innovation and aims to make molecular diagnostics a part of the daily fabric of life for everyone, ultimately improving global quality of life. The last round of investment for Seegene was a Venture Round investment led by IMM Investment on January 1, 2004.